MIT Holding, Inc. (OTCBB: MITD), in collaboration with MEVLABS and Georgia Southern University, have successfully tested prototype designs of the patent pending PROVECTOR™. This small dispensable device is designed to stop the development of pathogens and parasites found in mosquitoes that carry deadly diseases such as malaria, dengue fever, and West Nile virus.
Researchers have identified which sites and cell types within the respiratory tract are targeted by human versus avian influenza viruses, providing valuable insights into the pathogenesis of these divergent diseases.
In this retrospective cohort study that included 852 primary care physicians in Quebec, international medical graduates, physicians with high practice volumes and those who were in practice longer were more likely to prescribe antibiotics inappropriately.
A team led by researchers at the UCSF Positive Health Program has been named to receive $15 million over five years to expand understanding of the complex interactions between HIV and the immune systems of newly infected patients following HIV transmission.
GlaxoSmithKline and Anacor Pharmaceuticals announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialisation of novel medicines for viral and bacterial diseases. The collaboration provides GlaxoSmithKline access to Anacor’s proprietary boron-based chemistry for use against selected targets.
Robert E. Fontaine, M.D., CDC senior epidemiologist and Resident Advisor to the U.S. Field Epidemiology Training Program in Beijing, China, has been honored with the Friendship Award of 2007. The Friendship Award is the highest honor given by the Chinese government to recognize non-Chinese experts who have made outstanding contributions to China’s social and economic development.
Since it first appeared in Hong Kong in 1997, the H5N1 avian flu virus has been slowly evolving into a pathogen better equipped to infect humans. The final form of the virus, biomedical researchers fear, will be a highly pathogenic strain of influenza that spreads easily among humans.
The National Institute of Allergy and Infectious Diseases at the National Institutes of Health has awarded the University of Georgia College of Veterinary Medicine a $1.18 million grant to develop rabies virus vaccines. This award is the continuation of a previous four-year $837,000 grant issued by NIAID in 2002 to initiate the study.
The chemical process known as acetylation plays a central role in cytokine receptor signal transduction – a fundamental biochemical cascade inside cells that controls the activity of antiviral and tumor-suppressing genes.
Since it first appeared in Hong Kong in 1997, the H5N1 avian flu virus has been slowly evolving into a pathogen better equipped to infect humans. The final form of the virus, biomedical researchers fear, will be a highly pathogenic strain of influenza that spreads easily among humans.